Organogenesis Holdings (ORGO) Revenue (2017 - 2026)

Organogenesis Holdings' Revenue history runs 10 years deep, the most recent figure standing at $37.2 million for Q1 2026.

• On a quarterly basis, Revenue fell 57.06% year-over-year to $37.2 million in Q1 2026; TTM through Mar 2026 was $514.7 million, a 12.19% increase from a year earlier, with the FY2025 full-year figure at $564.2 million, up 17.04% from the prior year.
• Revenue declined to $37.2 million in Q1 2026 per ORGO's latest filing, from $225.6 million in the prior quarter.
• Across five years, Revenue topped out at $225.6 million in Q4 2025 and bottomed at $37.2 million in Q1 2026.
• The 5-year median for Revenue is $115.2 million (2024), against an average of $115.7 million.
• Across the five-year window, Revenue jumped 78.13% in 2025 and sank 57.06% in 2026, its largest moves.
• Year by year, Revenue stood at $115.5 million in 2022, then retreated by 13.73% to $99.7 million in 2023, then advanced by 27.1% to $126.7 million in 2024, then jumped by 78.13% to $225.6 million in 2025, then sank by 83.5% to $37.2 million in 2026.
• Per Business Quant, the three latest ORGO Revenue figures stand at $37.2 million (Q1 2026), $225.6 million (Q4 2025), and $150.9 million (Q3 2025).